We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Correspondence |

Thirty-one Episodes of Myelitis and Optic Neuritis in a Woman With Neuromyelitis Optica and Systemic Lupus Erythematosus—Reply

Julius Birnbaum, MD, MHS; Douglas A. Kerr, MD, PhD
Arch Neurol. 2010;67(6):779-780. doi:10.1001/archneurol.2010.111.
Text Size: A A A
Published online


In reply

We thank Pellkofer et al for their intriguing letter describing the fascinating case of a patient with SLE and concomitant NMO who had 31 recurrent flares of opticospinal disease. Similar to our case,1 such recurrent opticospinal flares occurred despite treatment with rituximab and suggest that, in such intractable cases, cotreatment with an additional immunosuppressive agent may be necessary. Their article adds to our recent findings that, especially in patients with systemic rheumatic syndromes such as SLE, recurrent attacks of myelitis frequently occur despite potent immunosuppressive therapy. We recently described 22 patients with SLE and myelitis, representing the largest cohort of such patients ever described.2 In our cohort, 11 patients presented with an initial clinical pattern that we have termed white-matter myelitis, characterized by early examination findings of spasticity and hyperreflexia. Nine of these 11 patients satisfied proposed diagnostic criteria for the NMO spectrum of syndromes.3 In these 11 patients, the number of recurrent attacks ranged from 2 to 12. This subset of patients was not only distinguished by the NMO-IgG autoantibody but by seropositivity for anti-Ro/SS-A autoantibody as well as the lupus anticoagulant/antiphospholipid autoantibody. In SLE patients with NMO, the immunologic derangements that are relevant to SLE—and that may not be seen in patients with idiopathic NMO—may modulate the response to rituximab. Complement-mediated lysis of pathogenic B cells may be impaired in patients with SLE, in whom SLE activity may be associated with hypocomplementemia.4 Additionally, a subset of patients with SLE may be deficient in the FcRIIIa allele, which may be important in antibody-mediated cytotoxicity of pathogenic B cells.5

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





June 1, 2010
Julius Birnbaum, MD, MHS; Douglas A. Kerr, MD, PhD
Arch Neurol. 2010;67(6):779-780. doi:10.1001/archneurol.2010.111.
June 1, 2010
Hannah L. Pellkofer, MD; Reinhard Hohlfeld, MD; Tania Kuempfel, MD
Arch Neurol. 2010;67(6):779-780. doi:10.1001/archneurol.2010.109.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

3 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles